These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2960699)

  • 1. Is phosphodiesterase inhibition arrhythmogenic? Electrophysiologic effects in pithed rats and in normoxic and hypoxic rabbit atria of enoximone, a new cardiotonic agent.
    Vaughan Williams EM
    J Clin Pharmacol; 1987 Feb; 27(2):91-100. PubMed ID: 2960699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of enoximone.
    Dage RC; Kariya T; Hsieh CP; Roebel LE; Cheng HC; Schnettler RA; Grisar JM
    Am J Cardiol; 1987 Aug; 60(5):10C-14C. PubMed ID: 2956861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The electrophysiologic effects of enoximone in patients with preexisting ventricular tachyarrhythmias.
    Miles WM; Heger JJ; Minardo JD; Klein LS; Prystowsky EN; Zipes DP
    Am Heart J; 1989 Jan; 117(1):112-21. PubMed ID: 2521415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties.
    Schneider J; Beck E; Heers C; Conrad C; de Chaffoy de Courcelles D; Wilffert B; Peters T
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Nov; 346(5):563-72. PubMed ID: 1470228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose enoximone in subjects awaiting cardiac transplantation. Clinical results and effects on beta-adrenergic receptors.
    Lee HR; Hershberger RE; Port JD; Rasmussen R; Renlund DG; O'Connell JB; Gilbert EM; Mealey PC; Volkman K; Menlove R
    J Thorac Cardiovasc Surg; 1991 Aug; 102(2):246-58. PubMed ID: 1650867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of a new inotropic agent, enoximone, in heart surgery].
    Gomar C; Fita G; Pomar JL; Valero R; Mulet J; Nalda MA
    Rev Esp Anestesiol Reanim; 1991; 38(2):121-6. PubMed ID: 1678896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.
    Kelso EJ; McDermott BJ; Silke B
    Br J Pharmacol; 1993 Dec; 110(4):1387-94. PubMed ID: 8306078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Electrophysiologic effects of enoximone].
    Brembilla-Perrot B; Beurrier D; Bock F; Danglas P
    Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():69-74. PubMed ID: 2147838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral and cardiac effects of a new phosphodiesterase inhibitor in comparison with enoximone.
    Schröder T; Hering JP; Foth H; Ferrari M; Sipinková I; Hellige G
    Arzneimittelforschung; 1994 Aug; 44(8):948-50. PubMed ID: 7945538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the phosphodiesterase inhibitor enoximone on the autonomic innervation of the isolated heart.
    Löffelholz K; Dressler H; Lindmar R
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S33-9. PubMed ID: 2480484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the cardiovascular activities of a new cardiotonic agent, MDL 17043 (1,3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazole-2-one).
    Roebel LE; Dage RC; Cheng HC; Woodward JK
    J Cardiovasc Pharmacol; 1982; 4(5):721-9. PubMed ID: 6182401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inotropic effect of enoximone and its potentiation of adrenoreceptor agonists.
    Latimer MD; Latimer RD; Oduro A
    J Cardiothorac Anesth; 1989 Oct; 3(5 Suppl 1):9. PubMed ID: 2535308
    [No Abstract]   [Full Text] [Related]  

  • 13. Physiologic response to the inotropic and vasodilator properties of enoximone.
    Janicki JS; Shroff SG; Weber KT
    Am J Cardiol; 1987 Aug; 60(5):15C-20C. PubMed ID: 2956862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac profile of EGIS-9377, a novel cardiotonic agent as a Ca2+ sensitizer with bradycardiac activity.
    Hattori Y; Ishitani T; Tomita F; Gando S; Yokoshiki H; Azuma M; Kemmotsu O; Kanno M
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):585-90. PubMed ID: 10598798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone].
    Holubarsch C; Hasenfuss G; Thierfelder L; Heiss HW; Just H
    Z Kardiol; 1991; 80 Suppl 4():35-40. PubMed ID: 1833895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative assessment of the effects of 'inodilators' on the myocardium in patients without primary cardiac insufficiency after coronary surgery: Part II--Enoximone.
    Redmann K; Lunkenheimer PP; Isringhaus H; Geiger A; Rettig G; Flameng W; Demeyre T; Engel C; Peterschmidt O
    Thorac Cardiovasc Surg; 1991 Jun; 39(3):129-32. PubMed ID: 1831936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actions of the novel vasodilator, flosequinan, in isolated ventricular cardiomyocytes.
    Kelso EJ; McDermott BJ; Silke B
    J Cardiovasc Pharmacol; 1995 Mar; 25(3):376-86. PubMed ID: 7769801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the inotropic mechanism of enoximone in guinea pig ventricular muscle.
    Jonas SE; Mörner N; Christley HM; Wohlfart B
    J Cardiovasc Pharmacol; 1990 Sep; 16(3):423-9. PubMed ID: 1700213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of phosphodiesterase inhibition on myocardial energetics in dilative cardiomyopathy.
    Hasenfuss G; Holubarsch C; Heiss WH; Bonzel T; Meinertz T; Just H
    Basic Res Cardiol; 1987; 82 Suppl 2():403-9. PubMed ID: 2959265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile.
    Dukes ID; Vaughan Williams EM
    Br J Pharmacol; 1985 Feb; 84(2):365-80. PubMed ID: 2858236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.